Post-earnings recap
Reported
Wed, Aug 5, 2026
EPS actual
$4.48
EPS est.
$4.37
EPS surprise
+2.63%
1-day move
+3.57%
Cencora, Inc. reported a better-than-expected EPS for Q3-2026, which contributed to a positive stock reaction, with shares rising by 3.57%. However, there was no revenue data provided, and management did not offer any guidance updates. Investors may be encouraged by the EPS beat, but the lack of additional information leaves some uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.48 | N/A | +2.63% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Cencora, Inc. is a major player in the health care distribution sector, focusing on delivering essential medical products and services. With a market cap of $59 billion, the company plays a crucial role in ensuring that health care providers have access to the medications and supplies they need to serve patients effectively.
Last quarter
In Q2-2026, Cencora reported an EPS of $4.75, slightly missing expectations. The stock reacted negatively, dropping 17.38% the following day.
EPS beat streak
1Q
EPS beat rate
88%
Avg EPS surprise
+3.47%
Avg 1-day reaction
-1.56%
Investors are cautiously optimistic about Cencora's upcoming earnings, especially after a series of mixed results in previous quarters. The market is looking for signs of recovery in profitability and revenue growth.
Bull case
If Cencora can exceed EPS expectations and show strong revenue growth, it could signal a turnaround, boosting investor confidence and stock price.
Bear case
Conversely, if the company misses EPS expectations again, it could lead to further declines in stock price, as seen in previous quarters.
Key metrics to watch
Earnings Per Share (EPS)
Expected to be around $4.75.EPS is a key indicator of the company's profitability and is closely watched by investors.
Revenue Growth
Not available.Revenue growth reflects the company's ability to expand its market share and meet increasing demand.
The print will turn on these.
Q1
Will Cencora's EPS exceed $4.75 this quarter?
A strong EPS could indicate improved profitability and restore investor confidence after recent misses.
Q2
What is the outlook for revenue growth in the upcoming quarters?
Investors will be looking for guidance on revenue trends to assess the company's growth potential.
Why consensus could be wrong
The Street may be underestimating Cencora's potential for recovery, especially given its strong historical EPS beat rate of 88%.
Supporting evidence
Options are pricing a 0.94% move, which is below the historical average of 5.64%.
The company's past performance shows that it often rebounds after a miss, suggesting potential for a positive surprise.
Key risk
If the EPS comes in above $4.75, it could shift the narrative and restore confidence in the stock.
Pre-commit to what would confirm each case.
The market is focused on whether Cencora can recover from recent earnings misses and show signs of growth.
Bull confirmed if
An EPS of $4.80 or higher would confirm the bull case, indicating strong profitability.
Bear confirmed if
An EPS below $4.70 would confirm the bear case, suggesting ongoing challenges.
What the market is pricing for the move.
Implied Move
±0.94%
Historical Avg
±5.7%
The options market is pricing in a relatively small move, suggesting that traders expect limited volatility around the earnings announcement.
Options are pricing ±0.9% while COR has averaged ±5.7% over the last 8 prints — setup is pricing cheap.
ATM IV
0.3%
30d HV
60.2%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing cheap setup in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$298,935.48
986 sh
1 insider
Net
$298,935.48
Net selling
Most Active Insiders· 1 open-market trade
$298,935.48
Net selling
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Cencora beats expectations, history suggests the stock could rise by around 0.61%, confirming a positive trend.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
A miss could lead to a significant decline, with history indicating an average drop of 17.38% following such outcomes.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Gross Margin
Not available.Gross margin indicates how efficiently the company is producing its goods relative to its sales.
Recent Transactions
Oct 1, 2026 · @ $303.18
986 sh
$298,935.48
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Net selling
Recent Transactions
Traded May 6, 2026 · disclosed Jun 19, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.